inPractice® - Sofosbuvir/Velpatasvir

Management of Hepatitis C Infection

Authors: Jordan J. Feld, MD, MPH; Hemant Shah, MD, MScCH HPTE (More Info)
Editor In Chief: Stefan Zeuzem, MD
Last Reviewed: 7/24/18 (What's New)

Summary

High SVR12 rates observed with 12 weeks of sofosbuvir/velpatasvir in phase III trials
- ASTRAL-1: SVR12 99% in genotype 1, 2, 4, 5, 6 HCV infection^{[Feld 2015]}
- ASTRAL-2: SVR12 99% vs 94% with 12-wks of sofosbuvir + ribavirin in genotype 2 HCV infection^{[Foster 2015]}

Action required

Login now to access all of your entitled content
or
View additional options to gain access to this content

Keywords: Hepatitis C-Treatment